- Home
- GLRE vs CTNM Comparison
GLRE vs CTNM Comparison
Compare GLRE & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GLRE | CTNM |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 480.5M |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GLRE | CTNM |
|---|---|---|
| Price | $17.39 | $13.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 163.9K | ★ 262.7K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | 0.46 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.86 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $3.35 |
| 52 Week High | $19.39 | $16.33 |
Technical Indicators
Market Signals| Indicator | GLRE | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 51.86 |
| Support Level | $12.46 | $11.62 |
| Resistance Level | $19.39 | $16.17 |
| Average True Range (ATR) | 0.61 | 0.94 |
| MACD | -0.19 | 0.11 |
| Stochastic Oscillator | 22.54 | 49.29 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.